NO984757L - Gliacellelinjeavledet, neurotropisk faktorreseptor - Google Patents

Gliacellelinjeavledet, neurotropisk faktorreseptor

Info

Publication number
NO984757L
NO984757L NO984757A NO984757A NO984757L NO 984757 L NO984757 L NO 984757L NO 984757 A NO984757 A NO 984757A NO 984757 A NO984757 A NO 984757A NO 984757 L NO984757 L NO 984757L
Authority
NO
Norway
Prior art keywords
gdnf
gdnfr
receptor
nervous system
present
Prior art date
Application number
NO984757A
Other languages
English (en)
Norwegian (no)
Other versions
NO984757D0 (no
Inventor
Gary M Fox
Shuqian Jing
Duanzhi Wen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO984757D0 publication Critical patent/NO984757D0/no
Publication of NO984757L publication Critical patent/NO984757L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
NO984757A 1996-04-22 1998-10-12 Gliacellelinjeavledet, neurotropisk faktorreseptor NO984757L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1590796P 1996-04-22 1996-04-22
US1722196P 1996-05-09 1996-05-09
US08/837,199 US6455277B1 (en) 1996-04-22 1997-04-14 Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
PCT/US1997/006281 WO1997040152A1 (fr) 1996-04-22 1997-04-15 Recepteur de gdnf

Publications (2)

Publication Number Publication Date
NO984757D0 NO984757D0 (no) 1998-10-12
NO984757L true NO984757L (no) 1998-12-21

Family

ID=27360445

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984757A NO984757L (no) 1996-04-22 1998-10-12 Gliacellelinjeavledet, neurotropisk faktorreseptor

Country Status (19)

Country Link
US (3) US6455277B1 (fr)
EP (1) EP0909316B1 (fr)
JP (1) JP2000509271A (fr)
KR (1) KR20000010571A (fr)
CN (1) CN1219967A (fr)
AT (1) ATE338115T1 (fr)
AU (1) AU720092B2 (fr)
BR (1) BR9708959A (fr)
CA (1) CA2250704C (fr)
CZ (1) CZ324598A3 (fr)
DE (1) DE69736597T2 (fr)
EA (1) EA002924B1 (fr)
ES (1) ES2271968T3 (fr)
HU (1) HUP9902640A3 (fr)
IL (1) IL126553A0 (fr)
NO (1) NO984757L (fr)
NZ (1) NZ332256A (fr)
SK (1) SK140398A3 (fr)
WO (1) WO1997040152A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) * 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6677135B1 (en) * 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
EE9800377A (et) * 1996-05-08 1999-04-15 Biogen, Incorporated Ret-i ligand (RetL) närvi- ja neerukasvu stimuleerimiseks
US20020068361A1 (en) * 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
CA2291608C (fr) * 1997-05-30 2004-04-13 Amgen Inc. Recepteurs du facteur neurotrope
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
FI20000394A0 (fi) * 2000-02-21 2000-02-21 Airaksinen Matti GFRa4:n sukuisia tai siitä johdettuja aineita sekä niiden käyttö
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
EP1807506B1 (fr) * 2004-10-08 2013-04-17 Georgia Tech Research Corporation Microencapsulation de cellules dans des hydrogels a l'aide de potentiels electrostatiques
WO2007008547A2 (fr) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Anticorps anti-sp35 et leurs utilisations
US20090246189A1 (en) * 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
EP3242893A1 (fr) 2015-01-08 2017-11-15 Biogen MA Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
EP3538560A4 (fr) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. Polypeptides de fusion gdnf et leurs procédés d'utilisation
RU2690498C1 (ru) * 2018-05-17 2019-06-04 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека
RU2732600C1 (ru) * 2019-12-26 2020-09-21 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях гипоксии, и способ ее получения
RU2752906C2 (ru) * 2019-12-26 2021-08-11 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях теплового шока, и способ ее получения

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
EP1243652A3 (fr) 1991-09-20 2003-03-26 Amgen Inc., Facteur neurotrophique dérivé des cellules gliales
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
US6455277B1 (en) 2002-09-24
NO984757D0 (no) 1998-10-12
BR9708959A (pt) 1999-08-03
ATE338115T1 (de) 2006-09-15
CA2250704C (fr) 2005-04-12
AU2730997A (en) 1997-11-12
NZ332256A (en) 2000-03-27
US20030175876A1 (en) 2003-09-18
AU720092B2 (en) 2000-05-25
EA199800933A1 (ru) 1999-04-29
IL126553A0 (en) 1999-08-17
SK140398A3 (en) 1999-04-13
EP0909316B1 (fr) 2006-08-30
DE69736597T2 (de) 2006-12-21
ES2271968T3 (es) 2007-04-16
DE69736597D1 (de) 2006-10-12
HUP9902640A2 (hu) 1999-11-29
EA002924B1 (ru) 2002-10-31
JP2000509271A (ja) 2000-07-25
KR20000010571A (ko) 2000-02-15
US20060166325A1 (en) 2006-07-27
WO1997040152A1 (fr) 1997-10-30
EP0909316A1 (fr) 1999-04-21
HUP9902640A3 (en) 2001-11-28
CZ324598A3 (cs) 1999-01-13
CA2250704A1 (fr) 1997-10-30
CN1219967A (zh) 1999-06-16

Similar Documents

Publication Publication Date Title
NO984757L (no) Gliacellelinjeavledet, neurotropisk faktorreseptor
Borasio et al. Involvement of ras p21 in neurotrophin-induced response of sensory, but not sympathetic neurons.
Omerbašić et al. Hypofunctional TrkA accounts for the absence of pain sensitization in the African naked mole-rat
Borroto-Escuela et al. Evidence for the existence of FGFR1–5-HT1A heteroreceptor complexes in the midbrain raphe 5-HT system
Seth et al. Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor
Wu et al. The coming of age of axonal neurotrophin signaling endosomes
Yap et al. Adaptor protein complex-4 (AP-4) is expressed in the central nervous system neurons and interacts with glutamate receptor δ2
Hoy et al. SynCAM1 recruits NMDA receptors via protein 4.1 B
Thompson et al. Overexpression of the GABAA receptor ε subunit results in insensitivity to anaesthetics
Feldman et al. Characterization of acid‐sensing ion channel expression in oligodendrocyte‐lineage cells
US20220396819A1 (en) Method for producing peptide having physiological activity, and peptide comprising short linker
Godeny et al. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor
CA2414355A1 (fr) Peptides lineaires amphipathiques et les compositions les contenant
WO1998054213A3 (fr) Recepteurs du facteur neurotrope
Tereshko et al. Primary cilia in the postnatal brain: Subcellular compartments for organizing neuromodulatory signaling
Ramasamy et al. NogoR1 and PirB signaling stimulates neural stem cell survival and proliferation
Kondo et al. Coexpression of GABAA receptor γ1 and γ2 subunits in the rat trigeminal ganglion
MACDONALD Mechanisms of action
WO1998054213B1 (fr) Recepteurs du facteur neurotrope
JPH08511949A (ja) Ｄ４ドーパミン受容体についての合成遺伝子
Park et al. Temporal and spatial expression of neurotrophins and their receptors during male germ cell development
Nakanishi et al. Determination of ionization efficiency of glycated and non-glycated peptides from the N-terminal of hemoglobin β-chain by electrospray ionization mass spectrometry
Songok et al. Structural modification of the tripeptide KPV by reductive “glycoalkylation” of the lysine residue
Einarsen et al. Functional properties of human neuronal Kv11 channels
Barbaras et al. Stable ß-Turns of Tripeptides in Water through Cation-π Interactions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application